On the Record · Acadia Pharmaceuticals
Acadia Pharmaceuticals acquisitions, on the record
The businesses Acadia Pharmaceuticals bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Levo TherapeuticsWord for word“We acquired worldwide rights to develop and commercialize ACP-101 with the acquisition of Levo Therapeutics in June 2022.” 10-K for 2023 | acquisition | June 2022 | — |
Neuren Pharmaceuticals Limited (Neuren)Word for word“In July 2023, the Company expanded its licensing agreement for trofinetide with Neuren to acquire rights to the drug outside of North America as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591.” 10-K for 2023 | agreed acquisition | July 2023 | — |
Neuren Pharmaceuticals Limited (Neuren) exclusive North American license for DAYBUEWord for word“The license agreement was accounted for as an asset acquisition and the upfront cash payment of $ 10.0 million was expensed to research and development in the third quarter of 2018 as there is no alternative use for the asset.” 10-K for 2023 | acquisition | — | — |
Stoke (RNA-based medicines license and collaboration)Word for word“Under the terms of the agreement, the Company paid Stoke a $ 60.0 million upfront payment which was accounted for as an asset acquisition and was expensed to research and development in the first quarter of 2022 as there is no alternative use for the asset.” 10-K for 2023 | agreed acquisition | — | — |
Neuren Pharmaceuticals Limited (Neuren), expanded agreement for trofinetide outside North America and NNZ-2591Word for word“Under the terms of the expanded agreement, Neuren received an upfront payment of $100.0 million and is eligible to receive up to an additional $426.3 million in milestone payments based on the achievement of certain commercial and sales milestones for trofinetide outside of North America and up to $831.3 million in milestone payments based on the achievement of certain development and sales milestones for NNZ-2591.” 10-K for 2024 | acquisition | — | $100.0 million |
Rare Pediatric Disease Priority Review Voucher (PRV)Word for word“In December 2024, we completed the sale of our PRV for $150 million before fees and expenses, of which we paid Neuren one-third of the net proceeds, pursuant to the license agreement between the companies.” 10-K for 2025 | divestiture | In December 2024 | $150 million |
Deal filings since 2016
- 2025-05-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-12-11 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-07-18 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-12-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-01-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Acadia Pharmaceuticals’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.